Seres Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Seres Therapeutics

06/08/2025 14:31

Seres Therapeutics Inc MCRB.OQ reported a quarterly adjusted loss of $2.27​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-4.40.  The mean expectation of four analysts for the quarter was for a loss of $2.49 per share. Wall Street expected results to range from $-2.75 to $-1.95 per share.

Reported revenue was zero​; analysts expected zero.

Seres Therapeutics Inc's reported EPS for the quarter was a loss of $2.27​.

The company reported a quarterly loss of $19.86 million.

Seres Therapeutics Inc shares had risen by 28.5% this quarter and lost 14.1% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 4.1% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Seres Therapeutics Inc is $14.00, about 2% below its last closing price of $14.28

This summary was machine generated from LSEG data August 6 at 01:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Jun. 30 2025
-2.49
-2.27
Beat
Mar. 31 2025
-0.54
-2.96
Missed
Dec. 31 2024
-3.94
-2.00
Beat
Sep. 30 2024
-4.91
-7.60
Missed